Business
WeightWatchers Announces Third Quarter 2025 Results
End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription Revenues of $26
About this update from Ww International, Inc.
[{"type":"text","content":"End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription Revenues of $26 million, up 35% year-over-year Net Loss of $58 million; Net Loss Margin of 33.4%; Adjusted EBITDA1 of $43 million and Adjusted EBITDA Margin1 of 24.9% Narrowing 2025 Guidance to the higher end of previous ranges for Revenue and Adjusted EBITDA1 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced its results for the third quarter of fiscal 2025 ended September 30, 20252 in this Earnings Press Release and a Shareholder Letter posted on the Company’s Corporate Website. Third Quarter 2025 Overview Q3 reflected a significantly strengthened balance sheet as the Company’s first full quarter post-restructuring, with total debt reduced by more than 70% (~$1.1 billion) and Cash at quarter end increasing to $170 million from $152 million at the end of Q2.Clinical Subscription Revenue growth remained strong at 35.3% year-over-year, with retention of members previously prescribed compounded semaglutide better than expected. Total Revenues declined 10.8% year-over-year.Net Loss of $58 million was negatively impacted by a $53 million charge for income tax expense. As a result, Net Loss Margin was 33.4%. Adjusted EBITDA1 was $43 million; Adjusted EBITDA Margin1 remained strong at 24.9% reflecting disciplined cost management across the business and timing of marketing spend.Execution of strategic priorities is advancing, with key initiatives launched including the new Menopause program, and strong progress across brand, digital, and clinical innovation.Added senior leaders across technology, experience, and international to further strengthen the executive team and accelerate execution.Narrowing 2025 Guidance to the higher end of previous ranges for Revenues to $695 - $700 million and Adjusted EBITDA1 to $145 - $150 million. “WeightWatchers is entering a new era, uniquely positioned at the intersection of medical innovation and behavioral science, to lead this rapidly evolving weight health market,” said Tara Comonte, CEO of WeightWatchers. “GLP-1s are a breakthrough in obesity care, but real success, with or without medication, comes from combining science, healthy habits, accountability, and connection...